Is Illumina Still a Good Stock to Buy?
The world's leading maker of DNA sequencing technology has a problem. It's been less than two years since the Federal Trade Commission (FTC) successfully sued to block a proposed acquisition from Illumina (NASDAQ: ILMN), and the agency is at it again. Recently, the government's antitrust watchdog started arguing against the acquisition of a company that's still in the developmental stage.
If the FTC's latest move makes you nervous about buying Illumina stock, you're not alone. However, this case promises to be extra challenging for the plaintiff. Here's why the government's attempt to block Illumina's proposed acquisition of GRAIL isn't a reason to remove this market leader from your list of stocks to buy.
Image source: Getty Images.
Source Fool.com
